Brexucabtagene Autoleucel market Overview
Brexucabtagene Autoleucel is used with the brand name Tecartus. It is a cell-based gene therapy medication utilized in the treatment of mantle cell lymphoma in grown-ups. Moreover, Brexucabtagene Autoleucel is a chimeric antigen receptor T cell. It is the first cell-based gene therapy treatment affirmed by the U.S. Food and Drug Administration for the treatment of mantle cell lymphoma. Also, Brexucabtagene Autoleucel drug is a CD19-genetically modified autologous T cell.
While T cells are the part of the immune system that is evacuated by IV line through the procedure known as leukapheresis. In a laboratory, a chimeric antigen receptor is added to the T cells. These T cells are implanted back to the person's body. While CAR gives the ability to attack and kill malignant cells i.e. cancer to T cells.
CAR-T and TCR-T therapies have already revolutionized blood cancer treatment. Researchers Duke-NUS Medical School are examining the capability of turning this approach for the treatment of coronavirus patients.
Scientists also informed that these immunotherapies might also beneficial in the treatment of SARS-CoV-2, the virus resulting in the current outbreak. Various companies are working on cell therapies for coronavirus. AlloVir & Baylor College of Medicine are collaborated to produce an innovative therapy to treat the coronavirus.
Brexucabtagene Autoleucel market: Drivers and Restraints
Increasing cases of cancer and a rising variety of patients with failure response to varied treatments are witnessed to boosts the Brexucabtagene Autoleucel market growth globally. Additionally, increasing prevalence of cancer in geriatric & pediatric patients is projected to results in higher demand for an efficient and reliable treatment approach for the improvement of quality of patient’s lives.
Moreover, rising government activities for improving healthcare insurance framework and advancement in research & development activities for Brexucabtagene Autoleucel market is fueling the development of the Brexucabtagene Autoleucel market.
Meanwhile, side effects related to the mantle cell lymphoma treatment may result in cytokine release syndrome & other neurological disorders including coma, seizures, delirium and hallucinations. This factor is witnessed to restrain the Brexucabtagene Autoleucel market growth.
Brexucabtagene Autoleucel market: Overview
CD19 target antigens are witnessed to hold the dominant market share owing to the reality that end number of the companies were capable to receive their antigens approved & hence, commercialized them. Additionally, the diagnostic centers segment held the largest share owing to the rising research and development activities and the utilization of engineered cell therapy in molecular diagnostics.
However, the mantle cell lymphoma has a dominant market share as Tecartus therapy offers a therapeutic advantage for the patients who are suffering from the failure of conventional therapy. Meanwhile, Grade 1 is used in a variety of patients due to ease in administration & having lower side effects.
Brexucabtagene Autoleucel market: Regional Wise Outlook
Geographically, the Brexucabtagene Autoleucel market is segregated into seven regions viz. Asia Pacific, North America & Latin America, Eastern Europe Western Europe, Japan, & the Middle East and Africa.
North America is expected to dominate the global Brexucabtagene Autoleucel market followed by Europe & Asia Pacific. North America is expected to dominate the global Brexucabtagene Autoleucel market due to the rising venture and research & development activities for the improvement of malignancy treatments in this region.
Meanwhile, Asia Pacific is witnessed to show remarkable developments over the gauge time frame owing to the expanding number of worldwide players teaming up just as assembling contracts for mantle cell lymphoma therapy with local players in the region.
Brexucabtagene Autoleucel market: Key Market Participants
The key participants operating in the global Brexucabtagene Autoleucel market identified across the value chain are
- Kite Pharma Inc.
- Gilead Sciences
- Inc. Autolus.
- TrakCel Tmunity Therapeutics
- Bellicum Pharmaceuticals Inc.
- Sorrento Therapeutics
- Bluebird Inc.
- Minerva Biotechnologies Corporation
- CELGENE CORPORATION
- Fortress Biotech.
- Promab Biotechnologies
- Immune Therapeutics
- Ziopharm Oncology
- Inc Juno Therapeutics
- Novartis AG
- Celyad Eureka Therapeutics Inc.
- TILT Biotherapeutics
- Poseida Therapeutics Inc
In July the U.S. FDA has approved the Kite’s Tecartus i.e. CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma Meanwhile, the major players are concentrating on the vital merger and securing to upgrade their share in the worldwide Brexucabtagene Autoleucel market.
The report covers exhaust analysis on
- Brexucabtagene Autoleucel market Segments
- Brexucabtagene Autoleucel market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain)
- Eastern Europe (Poland, Russia)
- Asia Pacific (India, China ASEAN, Australia & New Zealand)
- The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
Brexucabtagene Autoleucel market Segmentation
The global Brexucabtagene Autoleucel market has been segmented based on product form, type, application, end-user and geography.
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- CD 19
- CD 20
- Diffuse Large B-Cell Lymphoma
- Multiple Myeloma
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Mantle cell lymphoma
- Research Institutes
- Biotechnological & pharmaceutical organizations
- Diagnostic centers or labs
- Academics or educational centers